How to Select a Local Agent for Medical Device Registration in Brazil

How to Select a Local Agent for Brazil Registration?

To select a local agent for medical device registration in Brazil, manufacturers should first confirm the target country, product risk classification, applicable regulatory pathway, and existing documentation base. Then evaluate technical files, quality management system, labeling, local agent, clinical evidence, and post-market maintenance requirements. AIMEILI recommends conducting a documentation gap assessment before formal submission to avoid project delays caused by unclear classification, documentation adequacy, or authorization arrangements.

Key Considerations for Chinese Manufacturers

For Chinese medical device companies, the most reliable approach is to first perform product classification and documentation gap assessment, then determine whether existing NMPA, CE, FDA, ISO 13485, or other market documentation can be reused. Brazil registration simultaneously impacts technical files, authorized representative, importer cooperation, label language, QMS evidence, and subsequent change and maintenance. If the project is driven solely by a list of required documents, issues such as model coverage, evidence chain consistency, label claims, and certificate control rights often lead to corrections or rework.

AIMEILI recommends integrating this question into a unified strategy for GHWP member states and multi-country market access. Use a set of reusable core technical documents to support localization for different markets, rather than creating documentation from scratch for each country.

Applicable Scenarios and Core Issues

Companies searching for guidance on local agent selection for Brazil registration typically need to determine whether existing documents support submission, whether a local agent or authorized representative is required, why timelines get extended, and which factors affect market launch. This issue often involves product classification, registration pathway, evidence chain, labeling localization, and post-market maintenance responsibilities.

If a company plans to enter multiple GHWP member states or markets in Southeast Asia, the Middle East, and Latin America, answering only one country's process may not suffice. A more valuable approach is to first create reusable versions of core technical files, QMS evidence, performance verification, clinical evidence, and labeling, then perform localized adjustments per each country's regulatory requirements.

Registration Judgment Logic

Companies should first confirm the product's intended use, mechanism of action, usage scenario, body contact method, duration of use, sterility, active/passive status, software or IVD attributes, then determine the risk classification and regulatory pathway. An incorrect pathway judgment will misdirect all subsequent translation, notarization, authorization, testing, and supplementary documentation.

For Brazil projects, also confirm the applicant entity and local responsibility boundaries: who holds the certificate, who handles regulatory communication, who manages import and post-market events, who triggers changes, and who maintains renewal documentation. If these issues are only vaguely addressed in commercial contracts, market control rights may be compromised later.

Documents and Evidence

Common documents include: product description, model/specification matrix, intended use, risk classification basis, ISO 13485 or applicable QMS certificate, technical files, performance verification reports, risk management files, clinical evaluation or evidence, labeling and instructions for use, authorization documents, existing registration certificates, manufacturer declarations, and post-market surveillance documentation.

The key to document quality is consistency rather than quantity. Label claims, test report coverage, clinical evidence scope, risk management conclusions, label warnings, and registration application information must support each other. Regulators focus on whether the product is safe, effective, and traceable for its intended use, not on the volume of submitted files.

Common Mistakes

• Treating the registration project as a simple document submission without first clarifying product classification, evidence coverage, and local responsibility boundaries.
• Directly translating NMPA documents without rearranging the evidence per Brazil's regulatory pathway.
• Including too many model variants with insufficient coverage by test reports, clinical evidence, or labeling.
• Selecting a local agent solely based on sales cooperation without defining regulatory responsibilities, certificate control rights, and post-market maintenance duties.
• Inconsistency across labeling, instructions, promotional materials, and registration documents, leading to corrections or post-market compliance risks.
• Failing to plan for multi-country documentation reuse, causing repeated preparation for each country and increased cost and timeline.

Preparation Checklist

Before starting a project, companies should use an internal checklist to confirm the documentation foundation and avoid discovering critical evidence gaps after submission.

• Compile the target product list, model/specification matrix, and intended use descriptions.
• Check whether existing NMPA, CE, FDA, or other market registrations are reusable.
• Prepare ISO 13485 certificate, test reports, risk management, clinical evaluation, and English labeling/IFU.
• Confirm the local agent or authorized representative's responsibilities, fees, certificate control rights, and exit mechanisms.
• Create a target country gap assessment table, identifying items requiring supplementary testing, translation, notarization, or additional declarations.

AIMEILI Perspective

AIMEILI advises that Brazil registration should not be understood as a one-time document submission, but managed as an overseas market access project. For companies planning to enter multiple countries, first establish clear core technical files and an evidence matrix, then convert per country requirements. This approach is generally faster, more stable, and easier for subsequent changes and renewals than preparing documents country by country.

From a project management standpoint, companies should control three key elements upfront: first, product classification and pathway determination; second, consistency of the documentation evidence chain; and third, defining the regulatory responsibility boundaries of local partners. If these three items remain unclear, even extensive documentation may lead to repeated rounds of corrections, agent communication issues, and post-market maintenance problems.

Frequently Asked Questions

Can domestic (NMPA) documents be used directly for Brazil registration? Domestic documents can serve as a basis but are typically not submittable as-is. Companies must adjust document structure, language, labeling, authorization documents, and evidence chain according to local regulatory requirements.

When is the best time to initiate a gap assessment? Immediately after confirming the target market and product list. The earlier the gap assessment is completed, the easier it is to arrange supplementary testing, translation, labeling adjustments, and agent selection.

Why does local agent selection affect registration quality? The local agent is usually involved in registration communication, changes, renewals, and post-market event handling. Unclear responsibilities can impact certificate control rights and subsequent market stability.

Project Execution Recommendations

During project execution, maintain a project ledger that tracks product list, model/specifications, registration pathway, document owner, translation status, testing status, local agent communication records, and estimated submission dates in one table. This helps identify documentation gaps in a timely manner and enables management to assess whether the project will impact launch plans.

For companies with existing registrations in multiple countries, also establish an evidence reuse matrix specifying which documents can serve as core evidence and which must be reissued or supplemented per country requirements. Particularly for labeling, clinical evaluation, risk management, performance verification, and QMS certificates, version consistency must be maintained.